Every single patient in a clinical trial walked away with no detectable tumour after receiving an immunotherapy drug for a specific form of bowel cancer — a result that researchers are calling unprecedented. The drug, dostarlimab (brand name Jemperli), produced a complete response in all 42 participants, raising hopes that surgery and chemotherapy may no longer be necessary for patients with this cancer type.
At a glance
- Dostarlimab trial: All 42 patients treated at Memorial Sloan Kettering Cancer Centre showed no evidence of disease on scans after completing the immunotherapy course.
- dMMR rectal cancer: The trial targeted locally advanced mismatch repair deficient rectal cancer, a subtype that accounts for roughly 5–10% of all rectal cancers.
- Standard treatment avoided: Current care for this cancer type involves chemotherapy, radiation, and surgery — procedures the trial results suggest may be replaceable for eligible patients.
What made these results so striking
A 100% complete response rate in oncology trials is extraordinarily rare. Most cancer treatments work well for a portion of patients and partially for others. The fact that every patient in this cohort showed no detectable tumour on imaging after treatment has surprised even seasoned researchers.
The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The first 24 patients have now been followed up for an average of 26.3 months, and the responses have held.
Principal investigator Andrea Cercek, of Memorial Sloan Kettering Cancer Centre, described the outcomes as showing “durable complete tumour regression without the need for life-altering treatment.” She added that she had seen firsthand the debilitating toll that standard treatment takes on patients, and called the dostarlimab results a potential turning point for this group.
How the drug works
Dostarlimab is a checkpoint inhibitor — a class of immunotherapy that works by releasing the brakes the cancer places on the body’s own immune system. Once those brakes are removed, immune cells can identify and attack tumour cells more effectively.
The drug targets cancers with a specific molecular characteristic called mismatch repair deficiency (dMMR). Cells with this defect accumulate a high number of mutations, which ironically makes them more visible to immune cells — and therefore more vulnerable to checkpoint inhibition. That biological quirk is likely why dostarlimab performs so well in this subtype.
Jemperli is already approved by the U.K.’s NHS for women with certain advanced or recurrent womb cancers that carry the same dMMR marker. This trial extends its potential reach.
What comes next
GSK, the pharmaceutical company behind Jemperli, has described the findings as “remarkable” and says they move science closer to understanding dostarlimab’s potential in a curative setting. The company is now running two larger registrational studies — AZUR-1 and AZUR-2 — designed to evaluate the drug in a broader set of colorectal cancers and generate the data needed for regulatory approval in this indication.
Hesham Abdullah, a senior vice president at GSK, said the results bring the company “one step closer to understanding the potential of dostarlimab in this curative-intent setting.”
For context, colorectal cancer is the third most commonly diagnosed cancer worldwide, and rectal cancers with the dMMR profile have historically been among the harder subtypes to treat without significant collateral damage to the patient’s quality of life. Avoiding a permanent colostomy bag or months of chemotherapy is not a minor benefit — it is life-changing.
What still needs to happen
This is a phase II trial, which means it is designed to test whether a treatment works — not yet to compare it head-to-head against standard care in a larger randomized setting. The cohort of 42 patients, while unanimously positive, is still small, and dMMR rectal cancer represents only a fraction of all bowel cancers. Longer follow-up will be needed to confirm that the complete responses remain durable over five or ten years — the time horizons that count most for patients and oncologists alike.
The trial also does not yet tell us whether dostarlimab could work in the far larger population of patients whose rectal cancers are mismatch repair proficient. That is a separate and harder scientific challenge. Still, for the specific group it targets, the signal here is as strong as clinical research produces, and the ongoing AZUR studies should clarify within a few years whether these results can be replicated at scale.
Bowel cancer research has moved quickly in recent years. Immunotherapy approaches in colorectal cancer have gained significant ground since the first checkpoint inhibitors were approved for this indication, and dostarlimab’s trial results represent one of the most dramatic single data points in that ongoing story.
Read more
For more on this story, see: Wales Online
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
